WAYNE, N.J., Dec. 18 /PRNewswire/ -- Bayer HealthCare today announced a charitable gift of $85,000 to the Multiple Sclerosis Foundation (MSF) to fund programs that provide aid and support for those living with multiple sclerosis (MS). The donation, made by the Bayer Foundation, is one of many each year that funds the programs of advocacy organizations that serve the needs of people affected by conditions that Bayer HealthCare products treat. The MSF offers a variety of support services to improve the quality of life for people with MS by enhancing comfort, safety and self-sufficiency. The donation from the Bayer Foundation will help fund the following MSF programs:
-- Patient Assistance Program - Provide one-time assistance to individuals with MS who are struggling financially and do not have access to or qualify for community, state, and national support agencies. -- Assistive Technology (AT) Program - Educates individuals with MS about available AT options that can help them function more independently in daily activities (including computers, mobility devices and vision aids), and assists in acquiring them. -- Home Care Grants - Serves as a liaison between people with MS and local resources to meet their specific caregiving needs, such as personal hygiene services, light housekeeping, grocery shopping and transportation to and from appointments. -- Brighter Tomorrow Grants - Provides goods or services to improve quality of life, such as eyeglasses, televisions, therapeutic equipment, mobility devices, and various home modifications. -- Cooling Program - Because heat aggravates MS symptoms, keeping the body cool can help people with MS cope with warm weather. This program offers body cooling items free of charge, including vests, neckties, wristbands, and hats. "Patient education and care are the cornerstones of our organization, and we are grateful for Bayer HealthCare's generosity," said Alan Segaloff, Executive Director, Multiple Sclerosis Foundation. "This charitable contribution will help us continue to motivate, educate and empower individuals with MS and their loved ones." MS is a chronic, progressive disease of the central nervous system that causes irreparable nerve damage. There are at least 400,000 Americans with MS, and every week about 200 new people are diagnosed with the condition. "We are proud to support and work with patient service groups, such as the MSF, which work tirelessly to improve the lives of people with MS," said Ludger Heeck, Ph.D., Vice President and General Manager, Specialized Therapeutics, Bayer HealthCare Pharmaceuticals. "This donation reflects our ongoing commitment to supporting those who are affected by the condition." The Bayer Foundation is an endowed 501(c)(3) entity and the primary source for Bayer HealthCare's philanthropic giving throughout the United States. It supports programs that enhance the quality of life, provide unique and enriching opportunities that connect diverse groups and ensure preparedness for tomorrow's leaders. About Multiple Sclerosis MS is a chronic, progressive disease of the central nervous system. Symptoms of MS vary from person to person and can be unpredictable. They may include: fatigue or tiredness, visual dysfunction in one or both eyes, weakness in one or more extremities, numbness and tingling in the face, arms, legs and trunk of the body, spasticity (muscle stiffness), dizziness, slurred speech and bladder dysfunction. About the Multiple Sclerosis Foundation The Multiple Sclerosis Foundation (MSF) is a publicly funded 501(c)(3) organization that was established in 1986. Headquartered in Fort Lauderdale, Florida, the MSF is a predominantly service-based organization that strives to ensure the best quality of life for those coping with MS by providing comprehensive support and educational programs. The MSF supports research into the cause and cure of MS, as well as investigations of various medical and complementary treatment options. About Bayer HealthCare Pharmaceuticals Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE Bayer HealthCare Pharmaceuticals